Zusammenfassung

• Objekte (1 geändert, 0 hinzugefügt, 0 gelöscht)
  • Wikiderm.EntryClass[0]

Details

Wikiderm.EntryClass[0]

Eintrag

...	...	@@ -71,7 +71,7 @@
71	71	(% class="Feature" %)Lit:(%%) Australas J Dermatol. 2023 Nov 27. [[http:~~/~~/doi.org/10.1111/ajd.14190>>url:http://doi.org/10.1111/ajd.14190]]
72	72
73	73	(% class="Eintrag-2" %)
74		-(% class="Feature" %)DD:(%%) (% class="Bullet" %)-(%%) (% class="Abbreviation" %)AGEP(%%)
	74	+(% class="Feature" %)DD:(%%) (% class="Bullet" %)-(%%) AGEP
75	75
76	76	(% class="Ebene-1" %)
77	77	(% class="Bullet" %)-(%%) Dermatitis herpetiformis
...	...	@@ -134,7 +134,7 @@
134	134	(% class="Feature" %)Lit:(%%) J Dermatol 2000; 27: 669-72
135	135
136	136	(% class="Ebene-3" %)
137		-(% class="Feature" %)PT:(%%) (% class="Abbreviation" %)CR(%%)
	137	+(% class="Feature" %)PT:(%%) CR
138	138
139	139	(% class="Ebene-3" %)
140	140	(% class="Feature" %)Altn:(%%) Maxacalcitol
...	...	@@ -143,7 +143,7 @@
143	143	(% class="Feature" %)Lit:(%%) Clin Exp Dermatol. 2015 May 19. [[http:~~/~~/doi.org/10.1111/ced.12680>>url:http://doi.org/10.1111/ced.12680]]
144	144
145	145	(% class="Ebene-5" %)
146		-(% class="Feature" %)Lit:(%%) (% class="Abbreviation" %)CR(%%)
	146	+(% class="Feature" %)Lit:(%%) CR
147	147
148	148	(% class="Ebene-2" %)
149	149	(% class="Bullet" %)-(%%) Dapson Gel
...	...	@@ -158,7 +158,7 @@
158	158	(% class="Bullet" %)-(%%) Dapson
159	159
160	160	(% class="Ebene-3" %)
161		-(% class="Feature" %)Bed:(%%) (% class="Abbreviation" %)GS(%%)
	161	+(% class="Feature" %)Bed:(%%) GS
162	162
163	163	(% class="Ebene-3" %)
164	164	(% class="Feature" %)Dos:(%%) 100-150 mg/Tag
...	...	@@ -197,8 +197,11 @@
197	197	(% class="Bullet" %)-(%%) Apremilast
198	198
199	199	(% class="Ebene-3" %)
200		-(% class="Feature" %)Lit:(%%) Australas J Dermatol. 2020 Feb 11. [[http:~~/~~/doi.org/10.1111/ajd.13253>>url:http://doi.org/10.1111/ajd.13253]]
	200	+(% class="Feature" %)Lit:(%%) (% class="Bullet" %)-(%%) Australas J Dermatol. 2020 Feb 11. [[http:~~/~~/doi.org/10.1111/ajd.13253>>url:http://doi.org/10.1111/ajd.13253]]
201	201
	202	+(% class="Ebene-3" %)
	203	+(% class="Bullet" %)-(%%) Australas J Dermatol. 2023 Aug;64(3):e310-e312. [[http:~~/~~/doi.org/10.1111/ajd.14073>>url:http://doi.org/10.1111/ajd.14073]]
	204	+
202	202	(% class="Ebene-2" %)
203	203	(% class="Bullet" %)-(%%) Anti-TNF-alpha
204	204
...	...	@@ -215,7 +215,7 @@
215	215	(% class="Feature" %)Lit:(%%) Ann Dermatol Venereol. 2013 Dec;140(12):797-800 (Frankreich)
216	216
217	217	(% class="Ebene-5" %)
218		-(% class="Feature" %)PT:(%%) (% class="Abbreviation" %)CR(%%)
	221	+(% class="Feature" %)PT:(%%) CR
219	219
220	220	(% class="Ebene-2" %)
221	221	(% class="Bullet" %)-(%%) Guselkumab